Related Experiment Video
Updated: Jan 29, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer
Xiaowei Wu1, Qingyu Luo1, Pengfei Zhao1
1State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China.
Abstract:
Chemoresistance is a severe outcome among patients with ovarian cancer that leads to a poor prognosis. MCL1 is an antiapoptotic member of the BCL-2 family that has been found to play an essential role in advancing chemoresistance and could be a promising target for the treatment of ovarian cancer. Here, we found that deubiquitinating enzyme 3 (DUB3) interacts with and deubiquitinates MCL1 in the cytoplasm of ovarian cancer cells, which protects MCL1 from degradation. Furthermore, we identified that O6-methylguanine-DNA methyltransferase (MGMT) is a key activator of DUB3 transcription, and that the MGMT inhibitor PaTrin-2 effectively suppresses ovarian cancer cells with elevated MGMT-DUB3-MCL1 expression both in vitro and in vivo. Most interestingly, we found that histone deacetylase inhibitors (HDACis) could significantly activate MGMT/DUB3 expression; the combined administration of HDACis and PaTrin-2 led to the ideal therapeutic effect. Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
Insights
Deubiquitinating enzyme 3 (DUB3) protects chemoresistance in ovarian cancer by stabilizing MCL1. Inhibiting the O6-methylguanine-DNA methyltransferase (MGMT)-DUB3-MCL1 axis with PaTrin-2 and HDAC inhibitors offers a promising therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chemoresistance in ovarian cancer leads to poor patient prognosis.
- The antiapoptotic protein MCL1 is crucial for chemoresistance and is a potential therapeutic target.
Purpose of the Study:
- To elucidate the regulatory mechanism of MCL1 in ovarian cancer chemoresistance.
- To identify novel therapeutic strategies targeting the identified pathway.
Main Methods:
- Investigated the interaction between DUB3 and MCL1 in ovarian cancer cells.
- Assessed the role of MGMT in regulating DUB3 transcription.
- Evaluated the efficacy of PaTrin-2 and HDAC inhibitors in vitro and in vivo.
Main Results:
- DUB3 deubiquitinates and protects MCL1 from degradation in ovarian cancer cells.
- MGMT transcriptionally activates DUB3, forming the MGMT-DUB3-MCL1 axis.
- PaTrin-2 suppressed ovarian cancer cells with elevated MGMT-DUB3-MCL1 expression.
- HDAC inhibitors activated MGMT/DUB3 expression, and their combination with PaTrin-2 yielded optimal therapeutic effects.
Conclusions:
- The MGMT-DUB3-MCL1 axis is essential for ovarian cancer chemoresistance.
- Combined treatment with HDAC inhibitors and PaTrin-2 effectively overcomes chemoresistance in ovarian cancer.
Related Concept Videos
RNA Stability
Nuclear Stability
To hold positively charged protons together...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Stability
The stability of an LTI system is determined by the roots of its characteristic equation, known as poles. A system is stable if it produces a bounded...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Ovarian Cycle

